Human T-cell Kv1.3 potassium channel blockers: new strategies for immunosuppression

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.10, Iss.6, 2000-06, pp. : 905-915

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840

By Wulff Heike

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 12, 2010-12 ,pp. : 1759-1765

Informa Healthcare

Access to resources Recommend Favorite

Novel Kv1.3 blockers for immunosuppression: WO2012155199

By Nguyen William

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 11, 2013-11 ,pp. : 1511-1516

Informa Healthcare

Access to resources Recommend Favorite

K+ Channel Blockers: Novel Tools to Inhibit T Cell Activation Leading to Specific Immunosuppression

Current Pharmaceutical Design, Vol. 12, Iss. 18, 2006-06 ,pp. : 2199-2220

Bentham Science Publishers

Access to resources Recommend Favorite

Voltage-Dependent Potassium Channels Kv1.3 and Kv1.5 in Human Cancer

Current Cancer Drug Targets, Vol. 9, Iss. 8, 2009-12 ,pp. : 904-914

Bentham Science Publishers

Access to resources Recommend Favorite

Kv1.3 potassium channel blockade as an approach to insulin resistance

By Desir Gary V

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 3, 2005-06 ,pp. : 571-579

Informa Healthcare

Access to resources Recommend Favorite